PrecisemAb Biotech Co., Ltd.

Noticing that antibody drugs can effectively cure diseases but at the same time cause severe adverse effects because of on-target toxicity, PrecisemAb, just like our name "Precise + mAb", is committed to creating the safest antibody therapy for patients. Our Universal Antibody Lock technology could "inactivate" antibody's binding ability by giving it a "Lock" on the biding site. The binding ability of antibody is limited in healthy tissues unless antibody encounters disease-associated protease in the diseased site. The cleaved Lock-antibody is designed to be specifically activated and neutralize the target antigen to inhibit the disease progression. Therefore, our antibody lock technology can effectively enhance antibody drugs’ selectivity in disease area and consequently reduce side effects caused by on-target toxicity. We at PrecisemAb deeply believe in scientific thinking and cultural diversity since innovations always come from diversity, and scientific mind can transform creativities into practical solutions. This belief is not only applied to how we work internally but also how we collaborate with external partners and how we contribute back to our society. For more information about us, please follow us on LinkedIn and visit our website！https://www.precisemab.com.tw/Home